{"name":"ERYtech Pharma","slug":"erytech-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ERY001","genericName":"ERY001","slug":"ery001","indication":"Advanced solid tumors, including colorectal and pancreatic cancer","status":"phase_2"},{"name":"Gemcitabine plus Abraxane","genericName":"Gemcitabine plus Abraxane","slug":"gemcitabine-plus-abraxane","indication":"Pancreatic cancer (phase 3 development)","status":"phase_3"},{"name":"Irinotecan plus 5-FU plus leucovorin","genericName":"Irinotecan plus 5-FU plus leucovorin","slug":"irinotecan-plus-5-fu-plus-leucovorin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"L-asparaginase","genericName":"L-asparaginase","slug":"l-asparaginase","indication":"Acute lymphoblastic leukemia (ALL)","status":"marketed"}]}],"pipeline":[{"name":"ERY001","genericName":"ERY001","slug":"ery001","phase":"phase_2","mechanism":"ERY001 encapsulates chemotherapeutic agents within red blood cells to enhance their delivery to tumors while reducing systemic toxicity.","indications":["Advanced solid tumors, including colorectal and pancreatic cancer"],"catalyst":""},{"name":"Gemcitabine plus Abraxane","genericName":"Gemcitabine plus Abraxane","slug":"gemcitabine-plus-abraxane","phase":"phase_3","mechanism":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Abraxane (paclitaxel albumin-bound) stabilizes microtubules to prevent cell division, together providing synergistic cytotoxic effects against cancer cells.","indications":["Pancreatic cancer (phase 3 development)"],"catalyst":""},{"name":"Irinotecan plus 5-FU plus leucovorin","genericName":"Irinotecan plus 5-FU plus leucovorin","slug":"irinotecan-plus-5-fu-plus-leucovorin","phase":"phase_3","mechanism":"This combination of irinotecan (a topoisomerase I inhibitor), 5-fluorouracil (a nucleotide analog), and leucovorin (a folate cofactor) works together to inhibit DNA synthesis and repair in cancer cells.","indications":["Metastatic colorectal cancer","Advanced gastrointestinal malignancies"],"catalyst":""},{"name":"L-asparaginase","genericName":"L-asparaginase","slug":"l-asparaginase","phase":"marketed","mechanism":"L-asparaginase depletes asparagine in the bloodstream, starving asparagine-dependent leukemic cells of an essential amino acid required for protein synthesis.","indications":["Acute lymphoblastic leukemia (ALL)","Acute myeloid leukemia (AML)","Lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2024-12-21","type":"pipeline","source":"Medical Dialogues","summary":"Sanofi appoints Jean-Paul Kress as Independent Director - Medical Dialogues","headline":"Sanofi appoints Jean-Paul Kress as Independent Director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOeWVaSXE0cjhfZ1hWV1c0TmJVS1hYaTRpU2JzY3ktb2RCNXRvSkVVRkk4MGlkMVJKTzNvNWFRN2xnbzZYNWdYSmhkaHhSN183bDBIMnFydWpKVnU0b2sxbF9xRHo5a0pfWVhZTHZWbVNKVzVSZWZwbUlqYXhBTXl2Qm9wdF8xeEY4LWRzLVlzY01BQWp4ZXRGOGVfVnl3aUd0VzFpQkxSSTBoSmNVMW1PWTk5RQ?oc=5","date":"2023-06-26","type":"deal","source":"Fierce Biotech","summary":"Erytech's merger with Pherecydes reaches the finish line after contentious few months - Fierce Biotech","headline":"Erytech's merger with Pherecydes reaches the finish line after contentious few months","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQRk1yX2czRlg0bVZxcFJ3LVZlOUlhc2ZtRjNrVVVWSjM2MDVSNmhKaV9fcXdZbVRmOXJrak1fTWs4Z1NkSnQzYUJ3M3JXSVBlc2JXZXNja204UDRxS3FWd2s4WWhBRl9TT29rOC1oZTZ4eVlfTGczTWd3NXBXaDFUSEJHazZ0X3E5Zk1Bc2RuRUxEQXNx?oc=5","date":"2023-06-23","type":"regulatory","source":"Yahoo Finance","summary":"ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 - Yahoo Finance","headline":"ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeti","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQeGg4VHNucjVSd0hBQXlReVladVdVSmNGanFmcmZLd0JZTlBkUFNHc0k0cXRET2NoOW1YUFlTSkxfRWItVW1fMTExNm4tWDZ2U1VJMjRJNWpZdHUtWGJOODFNakJUeG5QR0J0QjdkOGtMZE5iOGM2bkZQdkVWVUdOUnJTcEhkS0xISjZpTkZXd2NIbnkzbklQbVhqdXlrYWVYN3RLNDBmOGUzeHBxZ0xPT0R4YV9QN2x0TWFLWGlR?oc=5","date":"2023-06-05","type":"deal","source":"Fierce Biotech","summary":"Erytech accuses investor of trying to 'destabilize' biotech by opposing Pherecydes merger vote - Fierce Biotech","headline":"Erytech accuses investor of trying to 'destabilize' biotech by opposing Pherecydes merger vote","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQWGl6TE5tVTIwOWY4NWY5ZHAzaUVVWDRoa2VJZm84V0JJUUhhWjhta2VRQjNzRlVSdXpPS2xsNFdDaG5vTzIzeVBHM21GTml4WFdvWnFPQ3VOdFZzSWVlWnhEU3VQVXVIa0dQYWhCQnBpRm42Qi1aWjcyVXcwQ3dza19ZajBGbXlMcmtldFhZU1oxaGZrbENKQ0VqZ0NWaTV1eVpmbkVCaXRuUk95MTFHcmZJQ1h5dGplMVluNWxORQ?oc=5","date":"2023-02-16","type":"pipeline","source":"Fierce Biotech","summary":"By merging with struggling Erytech, Pherecydes spies opportunity to boost AMR strategy - Fierce Biotech","headline":"By merging with struggling Erytech, Pherecydes spies opportunity to boost AMR strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPcGx2aml1Wmh4NkRiV2s3ZjI1MTlRS0J2dUFwbXRtaHFNNW85UXlJYTJzTzVmYVo2dW1PY3diVi1xNjlsVkJkQXpaMl9VUTJENU5QaVZGX1pjdFNQcWh0bjBuZ0xOWDA3eW5SY0c0S0lxV0M2ZmN3THJQSXAzaU84a0hJZmtXcWJSNHlGbGR0dE5LMThEVmtqaHhCNVE2bnpSNmx5ZXBGMlhtS3hwbnhWUlY4MGZwRUc2?oc=5","date":"2022-11-22","type":"pipeline","source":"Fierce Pharma","summary":"Erytech pivots to extracellular vesicle drug delivery after lead candidate collapses - Fierce Pharma","headline":"Erytech pivots to extracellular vesicle drug delivery after lead candidate collapses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQNkNhUnBjZVROamF2NFRBa0NnV1NraHNBZm9BOWVSR0dBUVZqa0VNUDNNWnZKbHJRRHBDU0M4TmpldjZBU3l6SGlyakE4alNNMUxHNVY1UW9LN1RCSnNzV1J6bUNlb0FoQURtZXpCaE15OFhOOU4yVk5lUGtiVmdnZWx6T3ltQ2VBeS05dkxfZ1NSdlpqN0x3Rnh0TGZZc3lmVkZBQVBDLUZNaG11TWgxQ1liY3pwNGVkSnc?oc=5","date":"2022-05-19","type":"pipeline","source":"Fierce Pharma","summary":"Catalent throws down $175M on yet another manufacturing expansion - Fierce Pharma","headline":"Catalent throws down $175M on yet another manufacturing expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQngxYmg4aUs1QU1Pc3hMMm9fVnpkam1mclhTM2NUTXhlV203d3ozUGJzbndZeE9kc3BiV0xvdXNvOXJiVUJVQUpUanpTUDFtcU5xUmtyTDdwSFJ1X3VMQ0o2M3pncU5kUnZRSDlwNGRtNWxhcjRpaU1SeVlhVU1VbkpOMXNUeG96VllUZ3NjalJRY1dPaGN6cmxwSWZTSmxtSC1ZZVV4UktoZWVmcHFtRkNCUjR6eDJ1WGVJ?oc=5","date":"2022-04-25","type":"pipeline","source":"Fierce Pharma","summary":"Catalent snaps up New Jersey cell therapy plant for $44.5M days after revealing big biologics expansion - Fierce Pharma","headline":"Catalent snaps up New Jersey cell therapy plant for $44.5M days after revealing big biologics expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNOUp4TVNUUDdnTzk4em1JUThVeHRGV3kzWVdMVDY3emdheVI2LXBLQ2FKT19pbjRUcWFscmtqUjNrREJlUkw0VmRKUXJ5Q0dzWW5mdjV3T2lIMThQWFF2bGNmZ2VKUVBqcVNFQk1yaHlvLUFGTDNyNjFtaEd4NFV0dXNKaFhaZjY5dW9xeUR1cjd0RVBZRHVJVUtGYw?oc=5","date":"2021-11-17","type":"trial","source":"Pancreatic Cancer Action Network","summary":"Two Pancreatic Cancer Clinical Trials Fail to Improve Overall Survival - Pancreatic Cancer Action Network","headline":"Two Pancreatic Cancer Clinical Trials Fail to Improve Overall Survival","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNYVJ5d3VRM291cGh3QmJtS0lIempZR1plQ3B5dWU0WkQwN3JuSzFVQkpMQ25YRHNsUXlCUFdIMExVTzJ0aTRCTmdNUGVYalhHSUNsaU90MEFpbDdvLS0xLTBUOVFmX0JBdUlaMDhoVEt6Zk9IUDNrQzJKN3VJdXJaVjhGMlpWTDFzZk9pU0pSUWpGLVkybXg3WFJhNWg1QzRHTWtqekt3?oc=5","date":"2018-10-31","type":"trial","source":"twst.com","summary":"Gil Beyen, CEO and Chairman of ERYTECH Pharma, Explains the Phase III Cancer Cure from his Company - twst.com","headline":"Gil Beyen, CEO and Chairman of ERYTECH Pharma, Explains the Phase III Cancer Cure from his Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE5Tdk1uMjBFdkxsc21icGQ0S0lDVjZEZTdkalFyTjZvVm1jM0NyYW05Z1pMWEVEekZkXzBUWGNHZFY1OENwTWgzUGNzeUZFS0c3OHU4TjBrUzM5UQ?oc=5","date":"2017-11-29","type":"pipeline","source":"MarketBeat","summary":"ERYTECH Pharma (ERYP) Stock Price, News & Analysis - MarketBeat","headline":"ERYTECH Pharma (ERYP) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNV3Jjc0JIRVlhT05tRVd0TWtfWi1neHNPLWJxS3plRGlSdGQ0QkM5U0x0cTAtZU5GekRKQkVwQlBPUlUzdkVZeURRN1RLOFZrNW4zTmpIdWlMdzdFeThjeXZ6M2EzMHBkWllKeU9xOVgzejlQTHNuYjgwU2xmY3UyTXF3cHV4VnY0NGdidHlkd3NTb0Zw?oc=5","date":"2016-11-11","type":"deal","source":"Hunt Scanlon Media","summary":"Coulter Partners Recruits Chief Scientific Officer for ERYTECH Pharma - Hunt Scanlon Media","headline":"Coulter Partners Recruits Chief Scientific Officer for ERYTECH Pharma","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":1,"phase_3":2,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}